Mesa Laboratories (NASDAQ:MLAB) Hits New 1-Year High – Still a Buy?

Mesa Laboratories, Inc. (NASDAQ:MLAB) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $125.30 and last traded at $124.32, with a volume of 148315 shares traded. The stock had previously closed at $124.76.

Wall Street Analyst Weigh In

A number of brokerages have commented on MLAB. Weiss Ratings raised Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Wall Street Zen lowered Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, Wells Fargo & Company raised their target price on shares of Mesa Laboratories from $94.00 to $110.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $110.00.

Mesa Laboratories Trading Down 0.2%

The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73. The stock’s fifty day moving average price is $103.07 and its two-hundred day moving average price is $98.11. The company has a market capitalization of $712.04 million, a PE ratio of 151.37 and a beta of 0.92.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter. The company had revenue of $60.14 million for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.

Mesa Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Monday, August 31st will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s dividend payout ratio (DPR) is currently 76.19%.

Insider Activity

In other Mesa Laboratories news, Director John James Sullivan sold 7,093 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $112.80, for a total transaction of $800,090.40. Following the transaction, the director directly owned 17,834 shares of the company’s stock, valued at approximately $2,011,675.20. The trade was a 28.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director R Tony Tripeny acquired 900 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was bought at an average price of $113.69 per share, with a total value of $102,321.00. Following the completion of the acquisition, the director directly owned 6,298 shares in the company, valued at approximately $716,019.62. This represents a 16.67% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders sold 15,370 shares of company stock valued at $1,570,213. 2.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Mesa Laboratories

A number of large investors have recently modified their holdings of MLAB. Northwestern Mutual Wealth Management Co. raised its stake in Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 322 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Mesa Laboratories during the 4th quarter valued at approximately $27,000. Kestra Advisory Services LLC purchased a new position in shares of Mesa Laboratories during the 4th quarter worth approximately $55,000. BNP Paribas Financial Markets grew its holdings in shares of Mesa Laboratories by 115.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock worth $74,000 after acquiring an additional 421 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after acquiring an additional 684 shares during the period. Institutional investors own 90.60% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.